Bevazza 400 mg/16ml Injection is a monoclonal antibody used to treat metastatic breast cancer, non-small cell lung cancer, kidney cancer, cervical cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer, cancer of colon and rectum. Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Cancer can start in one region of the body and spread to other parts. This is referred to as metastasis.

Bevazza 400 mg/16ml Injection contains 'Bevacizumab' that works against vascular endothelial growth factor (VEGF) which is found on the lining of lymph and blood vessels. VEGF causes blood vessels to grow within tumours which provide oxygen and nutrients to the tumour. Inhibition of vascular endothelial growth factor limits the flow of oxygen and nutrients to the tumour, causing it to shrink or cease developing. Thus, it helps treat cancers.

Bevazza 400 mg/16ml Injection will be administered by a healthcare professional; do not self-administer. Based on your medical condition, your doctor will decide the dose and duration. In some cases, Bevazza 400 mg/16ml Injection may cause loss of appetite, constipation, fever, nosebleeds, change in speech, and taste. The majority of these side effects do not require medical treatment and fade away with time. However, consult your doctor if the side effects persist or worsen

Avoid taking Bevazza 400 mg/16ml Injection if you are pregnant. Use effective contraception during the treatment and for 6months after the last dose. Bevazza 400 mg/16ml Injection may cause sleepiness and fainting, so avoid driving while on treatment with Bevazza 400 mg/16ml Injection. Do not breastfeed during the treatment and for 6months after the last dose of Bevazza 400 mg/16ml Injection. Keep your doctor informed about your health condition and all the medicines you take to rule out any side effects.

Bevazza 400 mg/16ml Injection contains Bevacizumab, a monoclonal antibody used to treat metastatic breast cancer, non-small cell lung cancer, kidney cancer, cervical cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer, cancer of colon and rectum. Bevazza 400 mg/16ml Injection works against a protein called vascular endothelial growth factor (VEGF). Vascular endothelial growth factor (VEGF) inhibition limits the flow of oxygen and nutrients to the tumour cells, causing them to shrink or cease developing. Thus, it helps treat cancer.

Bevazza 400 mg/16ml Injection should only be taken under medical supervision. While taking Bevazza 400 mg/16ml Injection, the doctor will monitor your condition on a regular basis. If you have a history of allergic reactions to Bevazza 400 mg/16ml Injection or other medications, inform your doctor before taking it. Avoid taking Bevazza 400 mg/16ml Injection if you are pregnant. Use effective contraception during the treatment and for 6months after the last dose. Bevazza 400 mg/16ml Injection may cause sleepiness and fainting, so avoid driving while on treatment with Bevazza 400 mg/16ml Injection. Inform your doctor if you have/had high blood pressure, heart attack, stroke, bleeding problems, stomach/intestinal bleeding, perforation; if you had surgery in the past 28days/are due to have surgery. Do not breastfeed during the treatment and for 6months after the last dose of Bevazza 400 mg/16ml Injection. While taking Bevazza 400 mg/16ml Injection, please do not get any immunizations or vaccinations unless your doctor has approved it. Bevazza 400 mg/16ml Injection may increase the risk of bleeding, so be cautious and consult your doctor if you notice any bleeding or bruising.

• Your doctor may perform routine blood tests to evaluate your liver function, electrolyte levels, and blood cell count.
• Peripheral blood counts should be closely maintained during the treatment and, if necessary, until recovery.
• Wear protective clothing, sunglasses, and sunscreen to avoid unnecessary or prolonged exposure to sunlight and UV rays (such as tanning booths). Your skin may become sun-sensitive as a result of Bevazza 400 mg/16ml Injection.
• Peripheral blood counts should be evaluated on a regular basis throughout Bevazza 400 mg/16ml Injection treatment and until full recovery is achieved.